A multimodal approach to diabetic macular edema

Journal of Diabetes and its Complications

Volumn 30, Issue 3, 2016, Pages 545-553

  Au, Adrian ^a   Singh, Rishi P ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anti VEGF; Corticosteroids; Diabetic macular edema; Diabetic retinopathy; Laser photocoagulation

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; FLUOCINOLONE ACETONIDE; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT;

ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLINDNESS; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HEMORRHAGE; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR HYPERTENSION; LOW LEVEL LASER THERAPY; MULTIMODAL CHEMOTHERAPY; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA DETACHMENT; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE; DIABETIC RETINOPATHY; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; MACULAR EDEMA; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROCEDURES; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; BLINDNESS; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; VISUAL ACUITY;

EID: 84957083300     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.11.008     Document Type: Review

References (75)

1. A.P. Adamis, and A.J. Berman Immunological mechanisms in the pathogenesis of diabetic retinopathy Seminars in Immunopathology 30 2008 65 84 10.1007/s00281-008-0111-x
2. L.P. Aiello, R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, and T.S. Sabera G.L. King Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders The New England Journal of Medicine 331 1994 1480 1487 10.1056/NEJM199412013312203
3. Center of Disease Control National Center of Chronic Disease Prevention and Health Promotion Division of Diabetes Translation, Diabetic retinopathy Accessed June 25th, 2015 http://www.cdc.gov/visionhealth/pdf/factsheet.pdf
4. D.A. Antonetti, A.J. Barber, S.K. Bronson, W.M. Freeman, T.W. Gardner, and L.S. Jefferson JDRF Diabetic Retinopathy Center Group Diabetic Retinopathy Center Group Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease 55 9 2006 2401 2411 10.2337/db05-1635
5. T. Avitabile, A. Long, and A. Reibaldi Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema American Journal of Ophthalmology 140 4 2005 695 702 10.1016/j.ajo.2005.05.021
6. D.S. Boyer, Y.H. Yoon, R. Belfort, F. Bandello, R.K. Maturi, and A.J. Augustin Ozurdex MEAD Study Group Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema Ophthalmology 121 10 2014 1904 1914 10.1016/j.ophtha.2014.04.024
7. A. Brafman, I. Mett, M. Shafir, H. Gottlieb, G. Damari, and G. Gozlan-Kelner T. Shoshani Inhibition of oxygen-induced retinopathy in RTP801-deficient mice Investigative Ophthalmology & Visual Science 45 2004 3796 3805 10.1167/iovs.04-0052
8. D.M. Brown, M. Michels, P.K. Kaiser, J.S. Heier, J.P. Sy, T. Ianchulev, and ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration [ANCHOR study 1-year data] The New England Journal of Medicine 355 2006 1432 1444 10.1016/j.ophtha.2008.10.018
9. P.A. Campochiaro, D.M. Brown, A. Pearson, A. Ciulla, D. Boyer, and F.G. Holz FAME Study Group Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema Ophthalmology 118 4 2011 626 635 10.1016/j.ophtha.2010.12.028
10. P.A. Campochiaro, R. Channa, B.B. Berger, J.S. Heier, D.M. Brown, U. Fiedler, M.T. Stumpp Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase I/II study American Journal of Ophthalmology 115 4 2013 697 704 10.1016/j.ajo.2012.09.032
11. N. Cheung, P. Mitchell, and T.Y. Wong Diabetic retinopathy Lancet 376 9735 2010 124 136 10.1016/S0140-6736(09)62124-3
12. C.S.Y. Cheung, A.W.T. Wong, A. Lui, P.J. Kertes, R.G. Devenyi, and W.C. Lam Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections Ophthalmology 119 1609-1614 2012 10.1016/j.ophtha.2012.02.014
13. K. Csaky, and D.V. Do Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies American Journal of Ophthalmology 148 2009 647 656 10.1016/j.ajo.2009.06.014
14. T.M. Curtis, T.A. Gardiner, and A.W. Stitt Microvascular lesions of diabetic retinopathy: Clues toward understanding pathogenesis? Eye (London, England) 23 7 2009 1496 1508 10.1038/eye.2009.108
15. R.F. Degenring, and J.B. Jonas Serum levels of triamcinolone acetonide after intravitreal injection American Journal of Ophthalmology 137 6 2004 1142 1143
16. D.V. Do, Q.D. Nguyen, D. Boyer, U. Schmidt-Erfurth, D.M. Brown, and R. Vitti DA VINCI Study Group One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 119 8 2012 1658 1665 10.1016/j.ophtha.2012.02.010
17. J. Doukas, S. Mahesh, N. Umeda, S. Kachi, H. Akiyama, and K. Yokoi P.A. Campochiaro Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema Journal of Cellular Physiology 216 1 2008 29 37 10.1002/jcp.21426
18. DRCR.net A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema Ophthalmology 114 10 2007 1860 1867 10.1016/j.ophtha.2007.05.062
19. DRCR.net A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema Ophthalmology 115 9 2008 1447 1449 10.1016/j.ophtha.2008.06.015
20. DRCR.net Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema The New England Journal of Medicine 372 2015 1193 1203 10.1056/NEJMoa1414264
21. DRCR.net, M.J. Elman, L.P. Aiello, R.W. Beck, N.M. Bressler, and S.B. Bressler K.M. Miller Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 6 2010 1064 1077 10.1016/j.ophtha.2010.02.031
22. P.U. Dugel, M.S. Blumenkranz, J.A. Haller, G.A. Williams, W.A. Solley, and D.M. Klienman J. Naor A randomized dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema Ophthalmology 119 2012 121 131 10.1016/j.ophtha.2011.07.034
23. Early Treatment of Diabetic Retinopathy Study Photocoagulation for diabetic macular edema: Early treatment diabetic retinopathy study report number 1 Archives of Ophthalmology 103 12 1985 1796 1806
24. J.L. Edelman Differentiating intraocular glucocorticoids Ophthalmologica 224 1 2010 25 30 10.1159/000315158
25. K.G. Falavarjani, and Q.D. Nguyen Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature Eye 27 2013 787 794 10.1038/eye.2013.107
26. D.A. Friedman, J.O. Mason, T. Emond, and G. Mcgwin Povidone-iodine contact time and lid speculum use during intravitreal injection Retina 33 5 2013 975 981 10.1097/IAE.0b013e3182877585
27. H. Funatsu, H. Yamashita, T. Ikeda, T. Mimura, S. Eguchi, and S. Hori Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema Ophthalmology 110 9 2003 1690 1696
28. M.C. Gilles, I.L. McAllister, M. Zhu, W. Wong, D. Louis, and J.J. Arnold T.Y. Wong Intravitreal triamcinolone prior laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial Ophthalmology 118 5 2011 866 872 10.1016/j.ophtha.2010.09.029
29. M.C. Gilles, J.M. Simpson, C. Gaston, G. Hunt, H. Ali, and M. Zhu F. Sutter Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema Ophthalmology 116 11 2009 2182 2187 10.1016/j.ophtha.2009.04.049
30. M.C. Gillies, F.K. Sutter, J.M. Simpson, J. Larsson, H. Ali, and M. Zhu Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial Ophthalmology 113 9 2006 1533 1538
31. R.J. Glassock, and C. Winearls Ageing and the glomerular filtration rate: Truths and consequences Transactions of the American Clinical and Climatological Association 120 2009 419 428
32. M.S. Gordon, and D. Cunningham Managing patients treated with bevacizumab combination therapy Oncology 69 3 2005 25 33 10.1159/000088481
33. F. Hirai, M. Knudtson, B. Klein, and R. Klein Clinically significant macular edema and survival in type 1 and type 2 diabetes American Journal of Ophthalmology 145 2008 700 706 10.1016/j.ajo.2007.11.019
34. P. Hnik, D.S. Boyer, L.R. Grillone, J.G. Clement, S.P. Henry, and E.A. Green Antisense oligonucleotide therapy in diabetic retinopathy Journal of Diabetes Science and Technology 3 4 2009 924 930
35. J. Holash, S. Davis, N. Papadopoulos, S.D. Croll, L. Ho, and M. Russell J.S. Rudge VEGF-Trap: A VEGF blocker with potent antitumor effects Proceedings of the National Academy of Sciences of the United States of America 99 17 2002 11393 11398 10.1073/pnas.172398299
36. International Diabetes Foundation IDF Diabetes Atlas Sixth Edition Accessed June 25th, 2015 http://www.idf.org/sites/default/files/EN-6E-Atlas-Full-0.pdf
37. S.W. Kang, H.S. Sa, H.Y. Cho, and J.I. Kim Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema Archives of Ophthalmology 124 5 2006 653 658 10.1001/archopht.124.5.653
38. T.S. Kern Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy Experimental Diabetes Research 91503 2007 14 10.1155/2007/95103
39. S.J. Kim, and H.S. Toma Ophthalmic antibiotics and antimicrobial resistance 118 2011 1358 1363 10.1016/j.ophtha.2010.12.014
40. J.F. Korobelnik, D.V. Do, U. Schmidt-Erfurth, D.S. Boyer, F.G. Holz, and J.S. Heier O. Zeitz Intravitreal aflibercept for diabetic macular edema Ophthalmology 121 11 2014 2247 2254 10.1016/j.ophtha.2014.05.006
41. D.A. Lyall, A. Tey, B. Foot, S.T.D. Roxburgh, M. Virdi, and C. Robertson C.J. MacEwen Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: Incidence, features, risk factors, and outcomes Eye (London, England) 26 2012 1517 1526 10.1038/eye.2012.199
42. A. Martidis, J.S. Duker, P.B. Greenberg, A.H. Rogers, C.A. Puliafito, and E. Reichel C. Baumal Intravitreal triamcinolone for refractory diabetic macular edema Ophthalmology 1095 5 2002 920 927 10.1016/S0161-6420(02)00975-2
43. D.F. Martin, M.G. Maguire, S.L. Fine, G. Ying, G.J. Jaffe, and J.E. Grunwald F.L. Ferris Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results Ophthalmology 119 7 2012 1388 1398 10.1016/j.ophtha.2012.03.053
44. P. Massin, F. Bandello, J.G. Garweg, L.L. Hansen, S.P. Harding, and M. Larsen S. Wolf Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study 33 11 2010 2399 2405 10.2337/dc10-0493
45. C.A. McCannel Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies Retina 31 4 2011 654 661 10.1097/IAE.0b013e31820a67e4
46. Medscape Novel microinjection promising for macular degeneration Accessed Oct, 23rd 2015 http://www.medscape.com/viewarticle/848219
47. J.S. Mills, A. Bowers, C. Djerassi, H.J. Ringold, and Steroids CXXXVII Synthesis of a new class of potent cortical hormones. 6α,9α-Difluoro-16α-hydroxyprednisolone and its acetonide Journal of the American Chemical Society 82 13 1960 3399 3404 10.1021/ja01498a041
48. P. Mitchell, F. Bandello, U. Schmidt-Erfurth, G.E. Lang, P. Massin, and R.O. Schlingemann RESTORE study group The RESTORE study: Ranibizumab monotherapy or combined with laser versus monotherapy for diabetic macular edema Ophthalmology 118 4 2011 615 625 10.1016/j.ophtha.2011.01.031
49. A.A. Moshfeghi, P.J. Rosenfeld, H.W. Flynn Jr., S.G. Schwartz, J.L. Davis, and T.G. Murray C.A. Puliafito Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: A six-year experience at a university referral center Retina 31 4 2011 662 668 10.1097/IAE.0b013e31821067c4
50. J.M. Moss, S.R. Sanislo, and C.N. Ta A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections Ophthalmology 116 2009 1498 1501 10.1016/j.ophtha.2009.02.024
51. Q.D. Nguyen, D.M. Brown, D.M. Marcus, D.S. Boyer, S. Patel, and L. Feiner RISE and RIDE Research Group Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 4 2012 789 801 10.1016/j.ophtha.2011.12.03
52. Q.D. Nguyen, S.M. Shah, A.A. Khwaja, R. Channa, E. Hatef, and D.V. Do READ-2 Stuy Group Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study Ophthalmology 117 11 2010 2146 2151 10.1016/j.ophtha.2010.08.016
53. Ohr Pharmaceuticals Ohr Pharmaceutical announces successful end of phase II meeting with FDA on Squalamine Eye Drops (OHR-102 in Wet AMD) Accessed Oct 22nd, 2015 http://www.ohrpharmaceutical.com/media-center/press-releases/detail/304/ohr-pharmaceutical-announces-successful-end-of-phase-ii
54. P.A. Pearson, T.L. Comstock, M. Ip, D. Callanan, L.S. Morse, and P. Ashton D. Eliott Fluocinolone acetonide intravitreal implant for diabetic macular edema: A 3-year multicenter, randomized, controlled clinical trial Ophthalmology 118 8 2011 1580 1587 10.1016/j.ophtha.2011.02.048
55. R. Rajendram, S. Fraser-Bell, A. Kaines, M. Michaelides, R.D. Hamilton, and S.D. Esposti P.G. Hykin A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3 Archives of Ophthalmology 130 8 2012 872 979 10.1001/archophthalmol.2012.393
56. S. Rangasamy, P.G. McGuire, N.C. Franco, F. Monickaraj, S.R. Oruganti, and A. Das Chemokine mediated monocyte trafficking into the retina: Role of inflammation in alteration of blood-retinal barrier in diabetic retinopathy PloS One 9 10 2014 e108508 10.1371/journal.pone.0108508
57. V.R. Rao, E. Prescott, N.B. Shelke, R. Trivedi, P. Thomas, and C. Struble U.B. Kompella Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) Investigative Ophthalmology & Visual Science 51 10 2010 5198 5204 10.1167/iovs.09-5144
58. P.J. Rosenfeld, D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, and C.Y. Chung MARINA Study Group Ranibizumab for neovascular age-related macular degeneration The New England Journal of Medicine 355 2006 1419 1431 10.1056/NEJMoa054481
59. J.B. Saaddine, A.A. Honeycutt, K.M. Narayan, X. Zhang, R. Klein, and J.P. Boyle Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050 Archives of Ophthalmology 126 12 2008 1740 1747
60. F.A. Scappaticci, J.R. Skillings, S.N. Holden, H. Gerber, K. Miller, and F. Kabbinavar H. Hurwitz Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab Journal of the National Cancer Institute 99 2007 1232 1239 10.1093/jnci/djm086
61. L. Scheppke, E. Aguilar, R.F. Gariano, R. Jacobson, J. Hood, and J. Doukas M. Friedlander Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits The Journal of Clinical Investigation 118 6 2008 2337 2346 10.1172/JCI33361
62. Andrew M. Schimel, Ingrid U. Scott, and Harry W. Flynn Endophthalmitis after intravitreal injections: should the use of face masks be the standard of care? Archives of Ophthalmology 129 12 2011 1607 1609
63. I.U. Scott, R.P. Danis, S.B. Bressler, N.M. Bressler, D.J. Browning, H. Qin, and DRCR.net Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center involved clinically significant diabetic macular edema Retina 29 5 2009 613 617 10.1097/IAE.0b013e3181a2c07a
64. P.P. Sfikakis, V. Grigoropoulous, I. Emfietzoglou, G. Theodossiadis, N. Tentolouris, and E. Delicha P.G. Theodossiadis Infliximab for diabetic macular edema refractory to laser photocoagulation: A randomized, double-blind, placebo-controlled, crossover, 32-week study Diabetes Care 33 7 2010 1523 1528 10.2337/dc09-2372
65. M. Shibuya Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis Journal of Biochemistry and Molecular Biology 39 5 2006 469 478
66. H. Shimada, T. Hattori, R. Mori, H. Nakashizuka, K. Fujita, and M. Yuzawa Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask Graefe's Archive for Clinical and Experimental Ophthalmology 251 2013 1885 1890 10.1007/s00417-013-2274-y
67. T. Shoshani, A. Faerman, I. Mett, E. Zelin, T. Tenne, and S. Gorodin E. Feinstein Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis Molecular and Cellular Biology 22 7 2002 2283 2293 10.1128/MCB.22.7.2283-2293.2002
68. M. Soheilian, A. Ramezani, A. Obudi, B. Bijanzadeh, M. Salehipour, and M. Yaseri G.A. Peyman Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema Ophthalmology 116 6 2009 1142 1150 10.1016/j.ophtha.2009.01.011
69. M.G. Speaker, and J.A. Menikoff Prophylaxis of endophthalmitis with topical povidone-iodine Ophthalmology 98 12 1991 1769 1775 10.1016/S0161-6420(91)32052-9
70. M.W. Stewart, and P.J. Rosenfeld Predicted biological activity of intravitreal VEGF Trap The British Journal of Ophthalmology 92 2008 667 668 10.1136/bjo.2007.134874
71. P. Storey, M. Dollin, J. Pitcher, S. Reddy, J. Vojtko, and J. Vander Post-Injection Endophthalmitis Study Team The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection Ophthalmology 121 2014 283 289 10.1016/j.ophtha.2013.08.037
72. M. Tunc, H.I. Onder, and M. Kaya Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema Ophthalmology 112 6 2005 1086 1091 10.1016/j.ophtha.2004.12.039
73. M.I. Van Der Reis, E.C. La Heij, Y. De Jong-Hesse, P.J. Ringens, F. Hendrikse, and J.S. Schouten A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections Retina 31 8 2011 1449 1469 10.1097/IAE.0b013e3182278ab4
74. L. Wu, M.A. Martinez-Castellanos, H. Quiroz-Mercado, F. Arevalo, M.H. Berrocal, and M.E. Farah Pan American Collaborative Retina Group (PACORES) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES) Graefe's Archive for Clinical and Experimental Ophthalmology 246 1 2008 81 87 10.1007/s00417-007-0660-z
75. J.W. Yau, S.L. Rogers, R. Kawasaki, E.C. Lamoureux, and T. Bek Meta-Analysis for Eye Disease (META-EYE) Study Group Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 35 3 2012 556 564 10.2337/dc11-1909